Unchanging premature mortality trends in systemic lupus erythematosus: A general population-based study (1999-2014)

Rheumatology (United Kingdom)

Volumn 57, Issue 2, 2018, Pages 337-344

  Jorge, April M ^a   Lu, Na ^a   Zhang, Yuqing ^a   Rai, Sharan K ^a   Choi, Hyon K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Lupus; Mortality; Quality of care; Treatment; Trend analysis

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; PREMATURE MORTALITY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; CASE CONTROL STUDY; EPIDEMIOLOGY; FACTUAL DATABASE; MORTALITY; PROPORTIONAL HAZARDS MODEL; RHEUMATOID ARTHRITIS; TRENDS; UNITED KINGDOM;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MORTALITY, PREMATURE; PROPORTIONAL HAZARDS MODELS; UNITED KINGDOM;

EID: 85041550700     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex412     Document Type: Article

References (50)

1. Abu-Shakra M, Gladman DD, Urowitz MB. Mortality studies in SLE: how far can we improve survival of patients with SLE. Autoimmun Rev 2004;3:418-20
2. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004;3:423-53
3. Lee Y, Choi S, Ji J, Song G. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 2016;25:727-34
4. Urowitz M, Bookman A, Koehler B et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5
5. Aviña-Zubieta JA. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res 2017;69:849-56. [WorldCat]
6. Navarra SV, Leynes MS. Infections in systemic lupus erythematosus. Lupus 2010;19:1419-24
7. Bernatsky S, Boivin J-F, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550-7
8. Humphreys JH, Warner A, Chipping J. Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register. Arthritis Care Res 2014;66:1296-301
9. Zhang Y, Lu N, Peloquin C. Improved survival in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis 2017;76:408-13
10. Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31
11. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
12. Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol 2005;72:46-7
13. Nash A. Past trends in life expectancy. In: Mortality, 2014-based national population projections reference volume. Office for National Statistics, 2016 March. https://www. ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/compendium/nationalpopulationprojections/2014basedreferencevolumeseriespp2/chapter4mortality2014basednationalpopulationprojectionsreferencevolume (April 2017, date last accessed)
14. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251-5
15. NHS Digital: Read Codes. https://digital.nhs.uk/article/1104/Read-Codes (April 2017, date last accessed)
16. FDB Solutions: Multilex. www.fdbhealth.co.uk/solutions/multilex (April 2017, date last accessed)
17. Rees F, Doherty M, Grainge M et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis 2016;75:136-41
18. Herrett E, Thomas SL, Schoonen WM et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14
19. Khan NF, Perera R, Harper S et al. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010;11:1
20. Rod NH, Lange T, Andersen I et al. Additive interaction in survival analysis: use of the additive hazards model. Epidemiology 2012;23:733-7
21. Rees F, Doherty M, Grainge MJ et al. Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012. Rheumatology 2016;55:854-60
22. Bartels CM, Buhr KA, Goldberg JW et al. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol 2014;41:680-7
23. Her M, Kavanaugh A. Advances in use of immunomodulatory agents-a rheumatology perspective. Nat Rev Gastroenterol Hepatol 2015;12:363-8
24. Jordan N, D'Cruz D. Current and emerging treatment options in the management of lupus. Immunotargets Ther 2016;2:9-20
25. Rai SK, Yazdany J, Fortin PR, Avina-Zubieta JA. Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Res Ther 2015;17:143
26. Gatto M, Saccon F, Zen M et al. Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis. J Autoimmun 2016;74:94-105
27. Mosak J, Furie R. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy. Lupus 2013;22:361-71
28. Ruiz-Irastorza G, Khamashta MA. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 2008;17:271-3
29. Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64:1215-26
30. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
31. Isenberg DA, Petri M, Kalunian K et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:323-31
32. Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol 2014; 11:46-61
33. Dall'Era M. Treatment of lupus nephritis: current paradigms and emerging strategies. Curr Opin Rheumatol 2017;29:241-7
34. Hanly JG, O'Keeffe AG, Su L et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology 2016;55:252-62
35. Hak AE, Karlson EW, Feskanich D et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum 2009;61:1396-402
36. Schoenfeld S, Kasturi S, Costenbader K. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013;43:77-95
37. Aviña-Zubieta JA, Vostretsova K, De Vera MA, Sayre EC, Choi HK. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: a general population-based study. Semin Arthritis Rheum 2015;45:195-201
38. Goobie GC, Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol 2015;27:454-60
39. Lateef A, Petri M. Management of pregnancy in systemic lupus erythematosus. Nat Rev Rheumatol 2012;8:710-8
40. Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus 2013;22:1286-94
41. Bundhun PK, Soogund MZ, Huang F. Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: A meta-analysis of studies published between years 2001-2016. J Autoimmun 2017;79:17-27
42. Choi HK, Nguyen U-S, Niu J et al. Selection bias in rheumatic disease research. Nat Rev Rheumatol 2014;10:403-12
43. Ungprasert P, Sagar V, Crowson CS et al. Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria. Lupus 2017;26:240-7
44. Jarukitsopa S, Hoganson DD, Crowson CS et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res 2015;67:817-28
45. 2011 Census: Key Statistics for England and Wales, March 2011. Office for National Statistics; London: UK Statistics Authority, 2012
46. Coleman N, Halas G, Peeler W et al. From patient care to research: a validation study examining the factors contributing to data quality in a primary care electronic medical record database. BMC Fam Pract 2015;16:11
47. Jarman B, Aylin P. Death rates in England and Wales and the United States: variation with age, sex, and race. BMJ 2004;329:1367
48. Wohland P, Rees P, Nazroo J, Jagger C. Inequalities in healthy life expectancy between ethnic groups in England and Wales in 2001. Ethn Health 2015;20:341-53
49. Gruer L, Cezard G, Clark E et al. Life expectancy of different ethnic groups using death records linked to population census data for 4.62 million people in Scotland. J Epidemiol Commun Health 2016;70:1251-54
50. Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002;61:409-13